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Abstract
Background: For melanoma patients, timely identification and tumor thickness are directly
correlated with outcomes. COVID-19 impacted both patients’ ability and desire to see
physicians. We sought to identify whether the pandemic correlated with changes in melanoma
thickness at presentation and subsequent treatment timeline.

Methods: Retrospective chart review was performed on patients who underwent surgery for
melanoma in an academic center surgical oncology practice from May 2019 – September 2021.
Patients were split into two cohorts: “pre-pandemic” from May 2019 to May 2020 and
“pandemic,” after May 2020, representing when these patients received their initial diagnostic
biopsy. Demographic and melanoma-specific variables were recorded and analyzed.

Results: 112 patients were identified: 51 patients from the “pre-pandemic” and 61 from the
“pandemic” time period. The pandemic cohort more frequently presented with lesions greater
than 1mm thickness compared to pre-pandemic (68.8% v 49%, p=0.033) and were found to
have significantly more advanced T stage (p=0.02) and overall stage disease (p=0.022).
Additionally, trends show that for pandemic patients more time passed from patient-reported
lesion appearance/change to diagnostic biopsy (5.7 + 2.0 v 7.1 + 1.5 months, p=0.581), but less
time from biopsy to operation (42.9 + 2.4 v 52.9 + 5.0 days, p=0.06).

Conclusions: “Pandemic” patients presented with thicker melanoma lesions and more advanced
stage disease. These results may portend a dangerous trend toward later stage at presentation,
for melanoma and other cancers with rapid growth patterns, that will emerge as the prolonged
effects of the pandemic continue to impact patients’ presentation for medical care.
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Introduction
No one could have predicted what was to come with the advent of the SARS-CoV-2,
COVID-19 (COVID), pandemic. Beyond the catastrophic toll of the number of cases and deaths,
the COVID pandemic has inflicted a tremendous secondary effect on population health in the
preventative care fields and health screenings. Various lockdowns and restrictions around the
nation and re-prioritization of medical resources effectively ceased many preventative care
practices including cancer screening [1]. Another effect of the pandemic has been a decrease,
estimated at 40% or more, of face-to-face interactions between primary care physicians (PCPs)
and patients [2]. Additionally, in the northeast of the United States (New Jersey, Delaware, and
Pennsylvania) there was temporary closure of dermatologists’ offices which prevented in person
screening and care [3]. Considering PCPs and dermatologists are often the “gatekeepers” for
timely diagnosis and treatment for diseases such as melanoma, this undoubtedly affected
screening, diagnosis, and treatment during the pandemic worth investigating [4].
Melanoma tumor thickness is directly correlated to its disease-specific 10-year survival
rates [5]. Additionally, timely screening leading to earlier identification and diagnosis is proven to
result in thinner, or earlier stage, melanomas with superior outcomes [6]. Compounding this
issue of screening in the COVID pandemic, was the fact that many patients showed hesitancy to
present to their healthcare provider for issues unrelated to COVID, with one study estimating
that percentage ranging from 37-45% [7]. Updated recommendations and guidance were given
for surgical treatment of melanoma during the pandemic but that guidance could not have
accounted for patient preference or access for initial lesion evaluation in regional offices that
were forced to close [8]. While some studies have predicted that the pandemic would create
access issues for patients with melanoma, few have reported on the actual effects seen in the
US [8, 9].
Areas of the country that were particularly impacted by COVID-19 were affected by both
the forced closure of physicians’ offices and patients’ hesitancy to visit their physician for
3

changes in skin lesions. In this study we sought to identify if there were differences in melanoma
thickness at presentation between pre-pandemic and pandemic patient cohorts. Our hypothesis
was that due to the aforementioned reasons, melanoma patients would have thicker, more
advanced lesions in the pandemic cohort. Moreover, we attempted to elucidate where the delay
was resulting from in the screening, diagnosis, and treatment timeline by measuring the time
between changes noticed by the patient in their melanoma lesions, shave biopsies, initial office
visits with their surgeon, and eventual operation.
Methods and Materials
This study was determined to be exempt by the Institutional Review Board of Thomas Jefferson
University in 2021 (45 CFR 46.101; Control #21E.813).
Inclusion and Exclusion Criteria and Data Collection.
A retrospective chart review was performed on patients referred for surgical oncology
treatment of biopsy-proven melanoma to a single surgical oncology practice at an academic
medical center. The study dates were July 2019 – September 2021. Patients were divided into
two cohorts: “pre-pandemic” from May 2019 to May 2020 and “pandemic,” after May 2020.
These dates represented when the patients received their biopsy. Inclusion criteria included:
patients receiving surgery for melanoma. Exclusion criteria included a previous diagnosis of
melanoma and surgery solely for a site of metastatic melanoma.
Demographic data was recorded including age, gender, race, ethnicity, insurance status,
as well as personal or family history of any skin cancer.
Melanoma Tumor Characteristics and Diagnosis and Treatment Timeline Outcomes.
Melanoma-specific tumor characteristics were recorded and analyzed. These included
melanoma tumor thickness of lesion, histology, presence of ulceration, TNM staging, and overall
staging [10]. In cases where the thickness measured on shave biopsy and final wide local
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excision differed, the larger thickness was used for staging and analysis. The anatomic location
of the melanoma was recorded.
The time in days from initial biopsy to surgeon’s office as well as surgeon office visit to
operation were collected. When available, time in months between when the patient reported
noticing a lesion/change in lesion and biopsy was recorded.
Statistical Analysis.
Chi-square and Welch’s t test were used to compare categorical and continuous
outcome variables, respectively. For all comparisons two-sided statistical significance was set a
priori at p<0.05. All statistical analyses were performed using Stata/MP 17.1 (Statacorp, College
Station, TX).
Results
Demographics.
One hundred and twelve patients met inclusion criteria for analysis. There were 51
patients in the “pre-pandemic” cohort and 61 patients in the “pandemic” cohort. There were no
significant differences between the cohorts in the age, sex, race, ethnicity, or insurance status of
the patients (TABLE 1). In addition, there were no statistically significant differences between
the cohorts in personal history or family history of any skin cancers or histology type of the
melanoma lesion at time of diagnosis (TABLE 1).
Melanoma Tumor Characteristics.
The pandemic cohort more frequently presented with melanoma lesions thicker than
1mm compared to pre-pandemic (68.8% v 49%, p=0.033) (TABLE 2). The pandemic cohort also
more frequently presented with melanoma lesions with greater T stages compared to prepandemic (p=0.02) (TABLE 2). Additionally, on final pathology there was a statistically
significant difference in distribution of overall stage using the American Joint Committee on
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Cancer (AJCC) TNM staging system 8th edition, with 49.0% of patients presenting at overall
stage greater than Stage 1A in the “pre-pandemic” cohort compared to 68.9% in the pandemic
cohort (p=0.022) (TABLE 2) [10]. There were no statistically significant differences in presence
of ulceration, N stage, and M stage (TABLE 2). Although there was no significant difference in
location of melanoma between the cohorts, it is notable that the pandemic cohort had an
increased percentage of anterior trunk and upper extremity melanomas with a decreased
percentage of posterior trunk melanomas (TABLE 2).
Diagnosis and Treatment Timeline Outcomes.
In the pandemic cohort, trends showed a strong, but insignificant trend towards less time
passed from biopsy to operation (42.9 + 2.4 v 52.9 + 5.0 days, p=0.06) and from initial office
visit with a surgeon to operation (21.0 + 1.3 v 27.5 + 3.6 days, p=0.06) (TABLE 3). Interestingly
a non-significant trend was found for longer patient-reported time between patients’ noticing a
change in their lesion to initial diagnostic biopsy (5.7 + 2.0 v 7.1 + 1.5 months, p=0.581) (TABLE
3).
Discussion
The temporary closures and limited access to outpatient primary care and subspecialty
practices brought on by the COVID-19 pandemic presented a new barrier to healthcare for
patients outside of the traditional social determinants of health, especially in the northeast of the
country [3]. However, in the case of melanoma, where demographic factors are relatively
uniform, the effects of the pandemic serve as a noteworthy example of how access barriers can
result in later stage of disease at presentation. In particular, it highlights how the effect of
barriers to healthcare can impact patients prior to their interaction with the medical system.
Our study of a population of patients treated at an academic medical center, in a region
of the United States that was particularly impacted early in the pandemic, identified a significant
trend towards thicker melanoma lesions and later stage overall disease associated with the
pandemic. Another subtle, but noteworthy finding, was that in our study we observed relatively
6

more lesions in areas easily visualized by patients (i.e., upper extremity, anterior trunk) and less
lesions in those classically picked up by physicians (i.e., posterior trunk/flank) during the
pandemic. We also began to clarify what level of the care process most impacted the diagnosis
and treatment of these melanoma patients. Initially, the decreased time between diagnosis and
treatment in our study may be counterintuitive, but upon further contemplation is likely explained
by the tier prioritization system enacted by many institutions globally and in the US, which
placed emergency surgeries as well as cancer-related operations in the highest tiers [11]. Our
university hospital prioritized the surgical care of trauma, acute care, and cancer patients
throughout the height of the pandemic. Our surgical practice markedly increased the utilization
of telehealth for office visits to provide care while minimizing exposures. Interestingly, our
results demonstrate that these prioritization efforts during the height of the pandemic were
associated with a decrease in time between diagnostic biopsy and date of surgery as well as
time between the initial surgeon’s office visit and date of surgery for patients with malignant
melanoma. All of these findings highlight the complexity of barriers to access within the medical
system as well as the positive potential for prioritization efforts and technology to improve
efficiency of care delivery.
In the context of timely cancer screening and treatment, melanoma represents a
uniquely aggressive, routinely monitored cancer diagnosis. Specifically, doubling time for
melanoma is estimated to be around 94 days [12] as compared to 241 days for invasive breast
cancer [13], 440 days for 600 days for lung adenocarcinoma [14], and 936 days for colorectal
adenocarcinoma [15]. Our study sought to characterize the early pandemic effects given the
knowledge that this cancer would present itself earliest based on rapid growth pattern. In
addition, it was selected to serve as a warning for slower growing cancer diagnoses that will
inevitably be affected by the continued backlog of cancer screening and patient hesitation to
return for routine health screenings caused by the pandemic and its aftereffects.
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Increased tumor thickness is a well reported prognostic factor for melanoma outcomes
[16]. Our findings of a significant increase in presentation of melanomas with greater than 1 mm
in thickness and greater overall stage are consistent with those reported by Ricci et al who
observed an increase in melanoma thickness amongst Italian patients during their pre-pandemic
phase from 0.88mm to 1.96mm during the pandemic [17]. Interestingly, they also found an
increase in ulceration rates from 5.3% to 23.5%, which was not present in our cohort [17]. Of
note, Ricci et al also measured the number of new diagnoses of melanoma per day, which
decreased from 2.3 pre-pandemic, to 0.6 during the height of the pandemic, and rose only to 1.3
as the pandemic restrictions decreased [17]. This lends evidence to our concern that the true
deficit in these patients receiving timely treatment during the pandemic is time to diagnosis as
opposed to time between diagnosis and treatment.
Several helpful guidelines have been published on the surgical management of
malignant melanoma once diagnosed in the context of the resource-limited pandemic [18-21].
However, there exists a paucity of data and guidelines on how to bolster screening efforts
during these times [8, 22]. We suggest that disease-specific screening guidelines should be
created for melanoma among dermatologic, surgical, and cancer-related societies, to prepare
for a potential next practice-altering event. These may include promoting telehealth visits to
assess lesions that may be high risk and warrant a timely in-person office visit for biopsy.
Limitations of the study include that it is of a single academic institution in a region that
was impacted early and throughout the pandemic. While the generalizability of these findings
remains to be seen, we believe that these trends will likely persist in larger scale studies which
will inevitably be published in the years to come. Second, some of our findings, namely the time
between patient-reported lesion change and diagnosis/treatment variables, failed to reach
significance due to a lack of power with limited numbers of patients able to recall noticing their
lesion change as well as the potential for recall bias. Finally, our study was retrospective in
nature and, thus, can be subject to the biases associated with these types of studies.
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Conclusions
In this study we identified that patients presenting with melanoma during the height of
the pandemic had thicker lesions and presented at more advanced stages of melanoma. Based
on the results of this study, this concerning trend is more likely related to patients’ hesitancy or
barriers to present to the healthcare setting during the pandemic since the times from diagnostic
biopsy and initial surgeon’s office visit to operation were both shorter during the pandemic. It will
be important in the coming months and years to closely surveil for patients who may have been
lost to follow up in terms of their cancer screening. These findings of advanced stage, thick
melanomas may serve as the proverbial canary in a coal mine associated with lack of screening
and decreased access to care, as well as serve as an example of the need for screening
guidelines in pandemic or resource-limited circumstances.
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Tables
Table 1. Demographic data for "pre-pandemic" and "pandemic" patient cohorts
Pre-pandemic
(n = 51)
61.3 + 2.09
19 (37.3)
49 (96.1)
50 (98.0)

Age (years), Mean + SD
Female Sex, N (%)
White Race, N (%)
Non-Hispanic Ethnicity, N (%)
Insurance Status, N (%)
Medicare
22 (44.9)
Medicaid
1 (2.0)
Private
26 (53.1)
Personal History of Skin Cancer, N (%)
16 (31.4)
Family History of Skin Cancer, N (%)
13 (26.0)
Histology, N (%)
Superficial Spreading
19 (37.3)
Nodular
12 (23.5)
Lentigo Maligna
6 (11.8)
Acral Lentiginous
1 (1.9)
Other
13 (25.5)
Abbreviations: SD = standard deviation
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Pandemic
(n = 61)
63.0 + 1.98
29 (47.5)
60 (98.3)
59 (96.7)
20 (32.8)
2 (3.3)
39 (63.9)
18 (29.5)
18 (29.5)

17 (27.9)
14 (22.9)
2 (3.3)
3 (4.9)
25 (41.0)

P value
0.541
0.273
0.456
0.667
0.419

0.669
0.682
0.181

Table 2. Melanoma tumor characteristics for “pre-pandemic” and “pandemic” patient cohorts
Pre-pandemic Pandemic
P value
(n = 51)
(n = 61)
Thickness > 1mm, N (%)
25 (49.0)
42 (68.8)
0.033*
Ulceration Present, N (%)
15 (29.4)
17 (27.9)
0.857
T Stage, N (%)
0.02*
Tis
5 (9.8)
3 (4.9)
T1
22 (43.1)
16 (26.2)
T2
15 (29.4)
21 (34.4)
T3
5 (9.8)
12 (19.7)
T4
4 (7.8)
9 (14.8)
N Stage, N (%)
0.322
N0
48 (94.1)
54 (88.5)
cN0
23 (47.9)
19 (35.2)
pN0
25 (52.1)
35 (64.8)
N1
3 (5.9)
3 (4.9)
N2
0 (0)
3 (4.9)
N3
0 (0)
1 (1.7)
M Stage, N (%)
0.119
M0
49 (96.0)
61 (100)
M1
2 (4.0)
0 (0)
Overall Stage, N (%)
0.022*
0
5 (9.8)
2 (3.2)
1A
21 (41.2)
17 (27.9)
1B
10 (19.6)
16 (26.2)
2A
8 (15.7)
5 (8.2)
2B
1 (2.0)
9 (14.8)
2C
3 (5.9)
5 (8.2)
3
1 (2.0)
7 (11.5)
4
2 (3.8)
0 (0)
Location of Melanoma Lesion, N (%)
0.41
Head/Neck
6 (11.8)
7 (11.5)
Upper Extremity
15 (29.4)
24 (39.3)
Lower Extremity
13 (25.5)
15 (24.6)
Posterior Trunk/Back/Flank
15 (29.4)
10 (16.4)
Anterior Trunk
2 (3.9)
5 (8.2)
* denotes statistical significance; Abbreviations: SD = standard deviation
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Table 3. Diagnosis and Treatment Timeline for "pre-pandemic" and "pandemic" patient cohorts

Change in Lesion to Biopsy (months), Mean + SD

Biopsy to Initial Office Visit with Surgeon (days),
Mean + SD
Biopsy to Operation (days), Mean + SD
Initial Office Visit with Surgeon to Operation (days),
Mean + SD
Abbreviations: SD = standard deviation
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Pre-pandemic
(n = 11)
5.7 + 2.0
Pre-pandemic
(n = 51)
25.5 + 4.0
52.9 + 5.0
27.5 + 3.6

Pandemic P value
(n = 20)
7.1 + 1.5
0.581
Pandemic P value
(n = 61)
22.2 + 2.0
0.451
42.9 + 2.4
21.0 + 1.3

0.060
0.060

